- Home
- INSM vs GME Comparison
INSM vs GME Comparison
Compare INSM & GME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- GME
- Stock Information
- Founded
- INSM 1988
- GME 1996
- Country
- INSM United States
- GME United States
- Employees
- INSM N/A
- GME N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- GME Electronics Distribution
- Sector
- INSM Health Care
- GME Consumer Discretionary
- Exchange
- INSM Nasdaq
- GME Nasdaq
- Market Cap
- INSM 13.7B
- GME N/A
- IPO Year
- INSM 2000
- GME 2002
- Fundamental
- Price
- INSM $81.01
- GME $25.93
- Analyst Decision
- INSM Strong Buy
- GME Sell
- Analyst Count
- INSM 16
- GME 1
- Target Price
- INSM $84.29
- GME $10.00
- AVG Volume (30 Days)
- INSM 2.0M
- GME 6.6M
- Earning Date
- INSM 02-20-2025
- GME 03-25-2025
- Dividend Yield
- INSM N/A
- GME N/A
- EPS Growth
- INSM N/A
- GME N/A
- EPS
- INSM N/A
- GME 0.17
- Revenue
- INSM $342,958,000.00
- GME $4,334,000,000.00
- Revenue This Year
- INSM $19.74
- GME N/A
- Revenue Next Year
- INSM $43.16
- GME N/A
- P/E Ratio
- INSM N/A
- GME $152.72
- Revenue Growth
- INSM 22.13
- GME N/A
- 52 Week Low
- INSM $21.92
- GME $9.95
- 52 Week High
- INSM $81.25
- GME $64.83
- Technical
- Relative Strength Index (RSI)
- INSM 68.75
- GME 36.52
- Support Level
- INSM $74.47
- GME $25.50
- Resistance Level
- INSM $80.63
- GME $28.23
- Average True Range (ATR)
- INSM 2.98
- GME 1.03
- MACD
- INSM 0.55
- GME -0.31
- Stochastic Oscillator
- INSM 98.08
- GME 11.10
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.